Recent success of immunotherapy against checkpoint inhibitors targeting PD-L1 and programmed cell death-1 (PD-1) molecules in lung cancer have shown some promising results.32 However, the success rate is still low, indicating the need of the combined immunotherapy to target the lung tumour growth dependent on the genetic background of the host. Here, PDCD1 is linked to lung carcinoma.